Safety results of a phase III trial evaluating ADT plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403)

被引：0
|
作者：
Latorzeff, I.
Esterni, B.
Habibian, M.
Delplanque, G.
Theodore, C.
Baciuchka, M.
Dauba, J.
Laguerre, B.
Krakowski, I.
Gravis, G.
机构：
[1] Clin Pasteur, Toulouse, France
[2] Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France
[3] Fed Natl Ctr Lutte Canc, Paris, France
[4] Grp Hosp St Joseph, Paris, France
[5] Hop Foch, Suresnes, France
[6] Ctr Hosp Timone, Marseille, France
[7] Hop Layne, Mt De Marsan, France
[8] Ctr Eugene Marquis, Rennes, France
[9] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[10] INSERM, Dept Med Oncol, Inst Paoli Calmettes, UMR 891, F-13258 Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4681
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4681
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
    Gravis, Gwenaelle
    Boher, Jean-Marie
    Chen, Yu-Hui
    Liu, Glenn
    Fizazi, Karim
    Carducci, Michael A.
    Oudard, Stephane
    Joly, Florence
    Jarrard, David M.
    Soulie, Michel
    Eisenberger, Mario J.
    Habibian, Muriel
    Dreicer, Robert
    Garcia, Jorge A.
    Hussain, Maha H. M.
    Kohli, Manish
    Vogelzang, Nicholas J.
    Picus, Joel
    DiPaola, Robert
    Sweeney, Christopher
    EUROPEAN UROLOGY, 2018, 73 (06) : 847 - 855
  • [42] UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)
    Dhiantravan, Nattakorn
    Emmett, Louise
    Joshua, Anthony M.
    Pattison, David A.
    Francis, Roslyn J.
    Williams, Scott
    Sandhu, Shahneen
    Davis, Ian D.
    Vela, Ian
    Neha, Nitika
    Bressel, Mathias
    Murphy, Declan G.
    Hofman, Michael S.
    Azad, Arun A.
    BJU INTERNATIONAL, 2021, 128 (03) : 331 - 342
  • [43] ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial
    Marvaso, Giulia
    Corrao, Giulia
    Zaffaroni, Mattia
    Vincini, Maria Giulia
    Lorubbio, Chiara
    Gandini, Sara
    Fodor, Cristiana
    Netti, Sofia
    Zerini, Dario
    Luzzago, Stefano
    Mistretta, Francesco Alessandro
    Venetis, Konstantinos
    Cursano, Giulia
    Burla, Tiziana
    Mazzocco, Ketti
    Cattani, Federica
    Petralia, Giuseppe
    Fusco, Nicola
    Pravettoni, Gabriella
    Musi, Gennaro
    De Cobelli, Ottavio
    Tang, Chad
    Ost, Piet
    Palma, David A.
    Orecchia, Roberto
    Jereczek-Fossa, Barbara Alicja
    LANCET ONCOLOGY, 2025, 26 (03): : 300 - 311
  • [44] Androgen deprivation therapy alone or with docetaxel in hormone naive metastatic prostate cancer: Meta-analysis of randomized phase III trials.
    Zekri, Jamal
    Ahmad, Imran
    Imtiaz, Saba
    Al-Saadi, Rawan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial
    Araujo, John C.
    Trudel, Geralyn C.
    Saad, Fred
    Armstrong, Andrew J.
    Yu, Evan Y.
    Bellmunt, Joaquim
    Wilding, George
    McCaffrey, John
    Serrano, Sergio V.
    Matveev, Vsevolod
    Efstathiou, Eleni
    Oudard, Stephane
    Morris, Michael J.
    Sizer, Bruce
    Goebell, Peter J.
    De Bono, Johann Sebastian
    Paliwal, Prashni
    Durham, Susan
    Cheng, Shinta
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [46] Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124.
    Glode, L. Michael
    Tangen, Catherine M.
    Hussain, Maha
    Swanson, Gregory P.
    Wood, David Peter
    Sakr, Wael
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [47] Prognostic value of the modeled PSA kinetic parameter (KELIM) in prostate cancer patients with rising PSA after primary local therapy treated in a prospective phase III trial with ADT plus /- docetaxel
    Carrot, A.
    Elaidi, R-T.
    Colomban, O.
    Maillet, D.
    Tod, M.
    You, B.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S666 - S666
  • [48] Phase II trial evaluating concomitant docetaxel and samarium (TAXAM) in patients with hormone refractory metastatic prostate cancer.
    Widmark, A
    Modig, H
    Johansson, M
    Franzen, L
    Johansson, L
    Turesson, I
    Laurell, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 436S - 436S
  • [49] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
  • [50] Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) plus /- orteronel
    Lara, P. N.
    Mayerson, E.
    Gertz, E.
    Tangen, C.
    Goldkorn, A.
    van Loan, M.
    Hussain, M.
    Gupta, S.
    Zhang, J.
    Twardowski, P.
    Quinn, D. I.
    Vogelzang, N. J.
    Thompson, I.
    Agarwal, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 275 - U475
12345